VTVT

vTv Therapeutics Inc

21.03

Nov 06 • 3:59 PM ET -0.71 (-3.27%)

21.03

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Nov 05, 6:16 PMvTv Therapeutics beats fiscal Q3 2026 estimates with non-GAAP EPS -0.94 (+13% YoY) as CATT1 Phase 3 enrollment completes and HPPD wins FDA Orphan Drug status

Peers: BMEA LXRX RZLT SANA GUTS CRBP VRTX ENTX MBX AMLX

| Held by: VTI VXF IWC QQQS AVSC

Scroll to Statements

Index	-
Market Cap	83.15M
Enterprise Value	5.99M
Income	-7.68M
Sales	36.84M
Book/sh	17.37
Cash/sh	19.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	26
IPO	Jul 30, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	2.26
P/B	1.21
P/C	1.08
P/FCF	-
EV/EBITDA	-
EV/Sales	0.16
Quick Ratio	11.19
Current Ratio	11.19
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.91
EPS next Y	-3.95
EPS next Q	-1.08
EPS this Y	50.31%
EPS next Y	-148.34%
EPS next 5Y	-10.80%
EPS past 3/5Y	32.12% 14.99%
Sales past 3/5Y	- -
EPS Y/Y TTM	81.41%
Sales Y/Y TTM	216600.00%
EPS Q/Q	13.37%
Sales Q/Q	-
Earnings	Nov 05 AMC
EPS/Sales Surpr.	13.76% -

Insider Own	47.93%
Insider Trans	0.00%
Inst Own	30.76%
Inst Trans	9.78%
ROA	-8.62%
ROE	-10.95%
ROIC	-11.02%
Gross Margin	99.99%
Oper. Margin	-29.80%
Profit Margin	-20.84%
SMA20	-18.94%
SMA50	-28.04%
SMA200	-36.70%
Trades

Shs Outstand	4.01M
Shs Float	2.06M
Short Float	6.96%
Short Ratio	3.32
Short Interest	0.14M
52W High	44.00 -52.20%
52W Low	21.72 -3.18%
Volatility	7.48% 5.79%
ATR (14)	1.53
RSI (14)	23.12
Beta	0.31
Rel Volume	0.33
Avg Volume	43.15K
Volume	14,371

Perf Week	-16.45%
Perf Month	-30.09%
Perf Quarter	-38.67%
Perf Half Y	-31.45%
Perf YTD	-47.41%
Perf Year	-17.43%
Perf 3Y	37.63%
Perf 5Y	-63.23%
Perf 10Y	-89.09%
Recom	1.00
Target Price	57.38
Prev Close	21.74
Price	21.03
Change %	-3.27%

Consensus

Strong Buy

Avg. Price Target

$57.38

Implied Upside

+172.8%

Analysts10incl. previous ratings

Rating Distribution9 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 30, 2026	Initiated	RRodman & Renshaw	Buy	$67	+218.6%
Mar 12, 2026	Initiated	EEvercore ISI	Outperform	$44	+109.2%
Jan 23, 2026	Initiated	RRoth Capital	Buy	$58	+175.8%
Jan 05, 2026	Initiated	TTD Cowen	Buy	$67	+218.6%
Nov 19, 2025	Initiated	BBTIG Research	Buy	$40	+90.2%
May 30, 2019	Initiated	HH.C. Wainwright	Buy
Apr 10, 2018	Downgrade	SStifel	Buy → Hold	$12 → $1	-95.2%
Mar 08, 2018	Initiated	RROTH Capital	Buy	$17	-19.2%
Feb 08, 2018	Initiated	NNorthland Capital	Outperform	$28	+33.1%
Sep 26, 2016	Initiated	HH.C. Wainwright	Buy	$13	-38.2%
Sep 04, 2015	Initiated	CCanaccord Genuity	Buy	$15	-28.7%
Aug 24, 2015	Initiated	SStifel	Buy	$17	-19.2%
Aug 24, 2015	Initiated	PPiper Jaffray	Overweight	$24	+14.1%

Nov-05-26 04:33PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press) -9.53%
04:01PM	vTv Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-26 08:00AM	vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems (GlobeNewswire)
Oct-10-26 08:00AM	vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 (GlobeNewswire)
Oct-08-26 09:43AM	vTv Therapeutics stock jumps on FDA orphan drug status (Investing.com)
04:01PM	Loading…
Oct-07-26 04:01PM	vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease (GlobeNewswire)
Oct-06-26 08:00AM	vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 (GlobeNewswire)
Oct-05-26 08:00AM	vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) (GlobeNewswire)
Sep-15-26 04:05PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-26 08:00AM	vTv Therapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-19-26 04:05PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 08:22AM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press)
08:00AM	vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-26 04:05PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-26 04:05PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:45AM	Loading…
Jun-18-26 07:45AM	cAMPfield lands $180M to build gut disease drug (BioPharma Dive)
Jun-02-26 04:05PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-26 04:06PM	VTv Therapeutics: Q1 Earnings Snapshot (Associated Press) +21.36%
04:01PM	vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-26 04:15PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-07-26 08:00AM	vTv Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-07-26 04:15PM	vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-16-26 08:00AM	vTv Therapeutics to Participate in the 38th Annual ROTH Conference (GlobeNewswire) +14.57%
Mar-10-26 04:17PM	VTv Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-26 10:20AM	vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737 (Insider Monkey)
Feb-13-26 08:00AM	vTv Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.18%
Feb-02-26 08:00AM	vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 (GlobeNewswire) +8.19%
Jan-05-26 11:40AM	An Alzheimers Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? (Barchart) +7.02%
Dec-24-25 12:00PM	vTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should Know (Zacks)
04:05PM	Loading…
Dec-18-25 04:05PM	vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health (GlobeNewswire)
Nov-24-25 09:55AM	Does vTv Therapeutics (VTVT) Have the Potential to Rally 25.17% as Wall Street Analysts Expect? (Zacks)
Nov-11-25 12:00PM	All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy (Zacks)
Nov-06-25 05:42PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +5.07%
04:15PM	vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-09-25 08:00AM	vTv Therapeutics Announces New Appointments to its Scientific Advisory Board (GlobeNewswire)
Sep-15-25 08:00AM	vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting (GlobeNewswire)
Sep-03-25 04:57PM	UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
08:00AM	vTv Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-02-25 08:00AM	vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund (GlobeNewswire) +13.30%
Aug-12-25 04:53PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.35%
04:15PM	vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 08:00AM	vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin (GlobeNewswire) +10.52%
Aug-07-25 08:00AM	vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes (GlobeNewswire)
Jun-11-25 08:00AM	vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire)
May-19-25 09:00AM	vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin (GlobeNewswire)
May-15-25 04:19PM	VTv Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +5.16% -6.16%
04:01PM	vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
12:00PM	vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes (GlobeNewswire)
Mar-21-25 04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks) -5.48%
Mar-20-25 06:00PM	VTv Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
05:35PM	vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
Mar-18-25 11:06AM	FDA removes hold on vTvs cadisegliatin clinical programme for diabetes (Clinical Trials Arena) -7.70%
Mar-17-25 12:40PM	vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial (GuruFocus.com) +53.13%
11:46AM	FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress (GuruFocus.com)
08:30AM	vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes (GlobeNewswire)
Dec-09-24 07:33AM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER (PR Newswire)
Dec-02-24 04:05PM	vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 05:04PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +7.58% +7.12%
04:05PM	vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-24 05:01PM	vTv Therapeutics Faces License Agreement Termination (TipRanks)
Aug-08-24 05:26PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-24 11:23AM	FDA Puts Brake On vTv Therapeutics' Diabetes Candidate Program, Including Late-Stage Study, Stock Tanks (Benzinga) -24.53%
06:53AM	FDA places vTv Therapeuticss cadisegliatin programme on clinical hold (Clinical Trials Arena)
Jul-26-24 04:05PM	vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold (GlobeNewswire)
Jun-24-24 04:05PM	vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes (GlobeNewswire)
May-28-24 08:00AM	CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING (PR Newswire) -11.04%
May-20-24 12:00PM	CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER (PR Newswire)
May-09-24 10:57PM	VTVT Stock Earnings: vTv Therapeutics Reported Results for Q1 2024 (InvestorPlace) +5.22%
05:02PM	VTv Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:51PM	vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT (PR Newswire)
Mar-13-24 08:24AM	VTv Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-24 03:49PM	The Top 3 Healthcare Stocks to Buy on Weakness in 2024 (InvestorPlace) -15.35%
08:00AM	vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes (GlobeNewswire)
Mar-01-24 08:00AM	vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire) -5.70%
Feb-28-24 08:00AM	vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund (GlobeNewswire) +95.88%
Feb-22-24 04:00PM	CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE (PR Newswire)
Nov-09-23 05:06PM	VTv Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.82%
04:30PM	vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-23 08:00AM	vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference (GlobeNewswire)
Nov-02-23 08:00AM	vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-01-23 08:00AM	vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million (GlobeNewswire)
Sep-27-23 08:30AM	CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19 (PR Newswire)
Sep-26-23 08:30AM	Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer (PR Newswire)
Sep-22-23 05:22AM	3 Tumbling Stocks to Take a Chance On Now (InvestorPlace)
Sep-18-23 08:30AM	CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA (PR Newswire)
Aug-24-23 12:35PM	Is vTv Therapeutics Inc (VTVT) Modestly Undervalued? (GuruFocus.com) -20.58%
Aug-16-23 02:44PM	vTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaq (American City Business Journals)
Aug-11-23 04:37PM	VTv Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:30PM	vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-10-23 08:33AM	Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer (PR Newswire) +8.63%
Jun-16-23 08:00AM	vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline (GlobeNewswire) +5.21%
Jun-15-23 07:33AM	CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON (PR Newswire)
May-24-23 09:00AM	vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals (GlobeNewswire)
May-12-23 08:11AM	vTv Therapeutics Insider Ups Holding During Year \ (Simply Wall St.) -5.55%
May-11-23 04:33PM	VTv Therapeutics: Q1 Earnings Snapshot (AP Finance)

Show Previous News

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

CEOMr. Paul J. Sekhri

M.D.Dr. Michael Steven Tung M.B.A.

Chief Accounting OfficerMr. Barry K. Brown

Chief Scientific Officer & Executive VPDr. Carmen Valcarce Ph.D.

Executive VP & General CounselMs. Elizabeth M. Keiley

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTVT

vTv Therapeutics Inc

Upgrade your Finviz experience